Production, radiochemical separation and electrochemical concentration of No-carrier-added 52Mn: An emerging PET radiometal

IF 1.8 3区工程技术 Q3 CHEMISTRY, INORGANIC & NUCLEAR Applied Radiation and Isotopes Pub Date : 2025-02-05 DOI:10.1016/j.apradiso.2025.111707

Sourav Patra , Sanchita Ghosh , Khajan Singh , Suresh Chand Sharma , Sanjay Vishwanath Thakare , Rubel Chakravarty

{"title":"Production, radiochemical separation and electrochemical concentration of No-carrier-added 52Mn: An emerging PET radiometal","authors":"Sourav Patra , Sanchita Ghosh , Khajan Singh , Suresh Chand Sharma , Sanjay Vishwanath Thakare , Rubel Chakravarty","doi":"10.1016/j.apradiso.2025.111707","DOIUrl":null,"url":null,"abstract":"<div><div>Recently, there has been significant interest in 52Mn (T½ = 5.6 d) as a relatively long lived radiometal for PET imaging of cancer. In this study, we have produced 52Mn from natural Cr metallic powder target via 52Cr (p, n) 52Mn reaction in a particle accelerator. An efficient radiochemical separation method based on selective precipitation of Cr as Cr(OH)3 followed by electrochemical purification and concentration of 52Mn was developed for isolation of no-carrier-added (nca) 52Mn from the irradiated target. The overall radiochemical separation yield of the process was >75 %. After separation, 52Mn was obtained with >99.5 % radionuclidic purity and >97 % radiochemical purity. The apparent molar activity of 52Mn was determined to be 2.2 ± 0.1 MBq/nmol and it was found suitable for preparation of radiopharmaceuticals. As a proof of concept, [52Mn]Mn-DOTA-E[c(RGDfK)]2 was prepared with 98.8 ± 0.4 % radiolabeling yield and the radiochemical stability of the formulation was maintained over a period of 7 days under physiological conditions. Overall, this strategy is viable for obtaining nca 52Mn in a suitable form for radiopharmaceutical preparation and would potentially increase the availability of this radiometal for clinical PET imaging in foreseeable future.</div></div>","PeriodicalId":8096,"journal":{"name":"Applied Radiation and Isotopes","volume":"218 ","pages":"Article 111707"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Radiation and Isotopes","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969804325000521","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, there has been significant interest in ⁵²Mn (T_½ = 5.6 d) as a relatively long lived radiometal for PET imaging of cancer. In this study, we have produced ⁵²Mn from natural Cr metallic powder target via ⁵²Cr (p, n) ⁵²Mn reaction in a particle accelerator. An efficient radiochemical separation method based on selective precipitation of Cr as Cr(OH)₃ followed by electrochemical purification and concentration of ⁵²Mn was developed for isolation of no-carrier-added (nca) ⁵²Mn from the irradiated target. The overall radiochemical separation yield of the process was >75 %. After separation, ⁵²Mn was obtained with >99.5 % radionuclidic purity and >97 % radiochemical purity. The apparent molar activity of ⁵²Mn was determined to be 2.2 ± 0.1 MBq/nmol and it was found suitable for preparation of radiopharmaceuticals. As a proof of concept, [⁵²Mn]Mn-DOTA-E[c(RGDfK)]₂ was prepared with 98.8 ± 0.4 % radiolabeling yield and the radiochemical stability of the formulation was maintained over a period of 7 days under physiological conditions. Overall, this strategy is viable for obtaining nca ⁵²Mn in a suitable form for radiopharmaceutical preparation and would potentially increase the availability of this radiometal for clinical PET imaging in foreseeable future.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新型PET放射性金属无载流子52Mn的制备、放射化学分离和电化学富集

最近，人们对52Mn （T½= 5.6 d）作为一种寿命相对较长的放射性金属用于癌症PET成像产生了浓厚的兴趣。在本研究中，我们在粒子加速器中通过52Cr (p, n) 52Mn反应，以天然Cr金属粉末靶为原料制备了52Mn。提出了一种基于Cr(OH)3选择性沉淀、电化学净化和52Mn浓缩的高效放射化学分离方法，用于从辐照靶中分离无载流子添加（nca） 52Mn。该工艺的总放射化学分离率为75%。分离后得到52Mn，放射性核素纯度为99.5%，放射化学纯度为97%。52Mn的表观摩尔活性为2.2±0.1 MBq/nmol，适合用于放射性药物的制备。作为概念的证明，[52Mn]Mn-DOTA-E[c(RGDfK)) 2的放射性标记率为98.8±0.4%，在生理条件下，该制剂的放射化学稳定性保持了7天。总的来说，该策略对于获得适合放射性药物制剂形式的nca 52Mn是可行的，并且在可预见的将来可能会增加这种放射性金属在临床PET成像中的可用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Applied Radiation and Isotopes 工程技术-核科学技术

CiteScore

3.00

自引率

12.50%

发文量

406

审稿时长

13.5 months

期刊介绍： Applied Radiation and Isotopes provides a high quality medium for the publication of substantial, original and scientific and technological papers on the development and peaceful application of nuclear, radiation and radionuclide techniques in chemistry, physics, biochemistry, biology, medicine, security, engineering and in the earth, planetary and environmental sciences, all including dosimetry. Nuclear techniques are defined in the broadest sense and both experimental and theoretical papers are welcome. They include the development and use of α- and β-particles, X-rays and γ-rays, neutrons and other nuclear particles and radiations from all sources, including radionuclides, synchrotron sources, cyclotrons and reactors and from the natural environment. The journal aims to publish papers with significance to an international audience, containing substantial novelty and scientific impact. The Editors reserve the rights to reject, with or without external review, papers that do not meet these criteria. Papers dealing with radiation processing, i.e., where radiation is used to bring about a biological, chemical or physical change in a material, should be directed to our sister journal Radiation Physics and Chemistry.